CTNNA1 and myelodysplastic syndrome: Modification of CTNNA1 expression was shown to modulate apoptosis and proliferation in cell lines [7], while CDC25C was reported as recurrently mutated in familial platelet disorders with predisposition to acute myelogenous leukemia (FPD/AML) [27] and its dosage demonstrated as influencing the sensitivity to Lenalidomide in del(5q) MDS [28].